Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking the access of arachidonic acid to the active site of the cyclooxygenases (COXs). Because the prostanoids produced by COX-1 appear to play a physiological role (protection of the gastric mucosa, platelet aggregation, vascular homeostasis, maintenance of renal sodium-water balance) while those produced by COX-2 seem mainly to intervene in the inflammatory response and in certain processes associated with cell proliferation, the hypothesis has been put forward that the NSAIDs that are selective COX-2 inhibitors should theoretically be capable of maintaining NSAID therapeutic properties but also have fewer adverse side effects due to the maintenance of prostaglandin production at normal physiological levels. Current knowledge and key points: The hypothesis of COX isoenzyme selectivity has led to a proposed classification for COX inhibitors: 1) COX-1 selective inhibitors (low-dosage aspirin); 2) COX non-selective inhibitors (the majority of classified NSAIDs, which when administered over the long term, e.g., in cases of rheumatoid arthritis, cause duodenal ulcers in 20% of cases and gastric hemorrhage in 1-4% of cases/year); 3) COX-2 preferential inhibitors (meloxicam and nimesulide, which have fewer gastric side effects than standard NSAIDs, but which are not risk-free at high doses); 4) COX-2 selective inhibitors (celecoxib and rofecoxib). Preliminary clinical studies have shown that COX-2 selective inhibitors are as efficient as standard NSAIDs and have fewer adverse digestive side effects, thereby confirming the interest of this proposed classification. In the UK, the aforementioned studies have led to the commercialization of rofecoxib for the treatment of pain and osteoarthritis, while celecoxib has been introduced in medical practice in the USA and other countries for the treatment of rheumatoid arthritis and osteoarthritis. Future prospects and projects: Various epidemiological and laboratory studies have indicated that NSAIDs may be able to reduce the risk of cancer (colorectal cancer in particular) and Alzheimer's disease due to their inhibitory activity on COXs, especially COX-2. The therapeutic contribution of COX-2 specific inhibitors has to be more fully evaluated, particularly as these agents could delay the healing of duodenal ulcers and interfere with several COX-2-induced physiological functions. It is therefore suggested that until further information becomes available, this new class of NSAIDs should be used with caution in certain patient populations.

Exploring the Role of COX-2 in Alzheimer's Disease: Potential Therapeutic Implications of COX-2 inhibitors

Is There a Future for Cyclo-Oxygenase Inhibitors in Alzheimer???s Disease?

Integrated Communications Between Cyclooxygenase‐2 and Alzheimer's Disease

[COX Plays a Pivotal Role in the Progressive Neuronal Loss in Neurodegenerative Diseases].

[Cyclooxygenases, Lipoxygenases, Their Targeted Drugs and the Prevention of Alzheimer's Disease].

Quantification of COX-2 Level in Alzheimer's Disease Patients to Develop Potential Blood-Based Biomarker for Early Diagnosis and Therapeutic Target

Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1β and Aβ between glial and neuron cells.

[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]

A Therapeutic Role for Cyclooxygenase-2 Inhibitors in A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Cyclooxygenase-2 is Essential for Mediating the Effects of Calcium Ions on Stimulating Phosphorylation of Tau at the Sites of Ser 396 and Ser 404

Genetic model of selective COX2 inhibition improve learning and memory ability and brain pathological changes in 5xFAD mouse

New Horizons in the Roles and Associations of COX-2 and Novel Natural Inhibitors in Cardiovascular Diseases

The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review

The Multifunctional Anti-Inflammatory Drugs Used In The Therapy Of Alzheimer'S Disease

The role of COX-2 in intestinal inflammation and colorectal cancer

Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing

Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.

Synthesis and Molecular Docking Studies of New Ibuprofen Derivatives as AChE, BChE, and COX‐2 Inhibitors

Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008-2019)

Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective

Cyclooxygenase-2 in human pathological disease